NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Anderson M, Panteli D, Mossialos E. How can the EU support sustainable innovation and access to effective antibiotics? Policy options for existing and new medicines [Internet]. Copenhagen (Denmark): European Observatory on Health Systems and Policies; 2023. (Policy Brief, No. 51.)
How can the EU support sustainable innovation and access to effective antibiotics? Policy options for existing and new medicines [Internet].
Show details- Access to Medicine Foundation. Biotechs are saving the world from superbugs . Amsterdam: Access to Medicine Foundation; 2021. Can they also save themselves? (https:
//accesstomedicinefoundation .org/resource /biotechs-are-saving-the-world-from-superbugs-can-they-also-save-themselves, accessed 1 Feb 2023) - ADVANCE-ID. ADVANcing Clinical Evidence in Infectious Diseases (ADVANCE-ID) . Singapore: Saw Swee Hock School of Public Health; 2022. (https://sph
.nus.edu.sg /2022/11/advancing-clinical-evidence-in-infectious-diseases-advance-id, accessed 2 Dec 2022) - Aerts C, et al. The impact of the priority review voucher on research and development for tropical diseases. Pharmaceutical Medicine . 2022;36:189–197. (https://doi
.org/10.1007 /s40290-022-00427-x, accessed 1 Feb 2023) [PMC free article: PMC9217899] [PubMed: 35588350] - AFMPS. Fight against antibiotic resistance: Amukin (amikacin) available again . Brussels: Agence Fédérale des Medicaments et des Produits de Santé; 2022. (https://www
.afmps.be /fr/news/lutte_contre _lantibioresistance _amukin_amikacine_a_nouveau_disponible, accessed 23 Jan 2023) - AMR Action Fund. AMR Action Fund opens European office . AMR Action Fund: Press releases; 2022. (https://www
.amractionfund .com/blog-2022/amr-action-fund-opens-european-office, accessed 2 Dec 2022) - AMR Industry Alliance. Making antibiotics responsibly: A common manufacturing framework to tackle antimicrobial resistance . Geneva: AMR Industry Alliance; 2019. (https://www
.amrindustryalliance .org/wp-content /uploads/2019/11 /Making-antibiotics-responsibly _A-common-manufacturing-framework-to-tackle-AMR.pdf, accessed 1 Feb 2023) - Anderson M, et al. Averting the AMR crisis: What are the avenues for policy action for countries in Europe? Copenhagen: European Observatory on Health Systems and Policies; 2019. Policy Brief 52 (https://apps
.who.int /iris/handle/10665/331973, accessed 1 Feb 2023) [PubMed: 31287637] - Anderson M, Forman R, Mossialos E. Navigating the role of the EU Health Emergency Preparedness and Response Authority (HERA) in Europe and beyond. The Lancet Regional Health – Europe . 2021;9:100203. (https://doi
.org/10.1016/j .lanepe.2021.100203, accessed 1 Feb 2023) [PMC free article: PMC8500702] [PubMed: 34661186] - Anderson M, Wouters OJ, Mossialos E. Transferable exclusivity extensions to stimulate antibiotic research and development: What is at stake? The Lancet Microbe . 2022 online (https://doi
.org/10.1016 /S2666-5247(22)00336-6, accessed 1 Feb 2023) [PubMed: 36470300] - Årdal C, Lacotte Y, Ploy M-C., on behalf of the European Union Joint Action on Antimicrobial Resistance and Healthcare-Associated Infections (EU-JAMRAI). Financing pull mechanisms for antibiotic-related innovation: Opportunities for Europe. Clinical Infectious Diseases . 2020;71(8):1994–1999. (https://doi
.org/10.1093/cid/ciaa153, accessed 1 Feb 2023) - Årdal C, Lacotte Y, Ploy M-C. Improving access to essential antibiotics . EU-JAMRAI: Policy Brief; 2021. (https://eu-jamrai
.eu /wp-content/uploads/2021/07/1 .3.1_Policy _brief_Improving_access _to_essential_antibiotic.pdf, accessed 1 Feb 2023) - Årdal C, et al. An antibiotic’s journey from marketing authorization to use, Norway. Bulletin of the World Health Organization . 2017;95:220–226. (https://doi
.org/10.2471/BLT.16.172874, accessed 1 Feb 2023) [PMC free article: PMC5328106] [PubMed: 28250535] - Årdal C, et al. Revitalizing the antibiotic pipeline: Stimulating innovation while driving sustainable use and global access . 2018. DRIVE-AB report (http://drive-ab
.eu/wp-content /uploads/2018 /01/CHHJ5467-Drive-AB-Main-Report-180319-WEB.pdf, accessed 1 Feb 2023) - Årdal C, et al. Supply chain transparency and the availability of essential medicines. Bulletin of the World Health Organization . 2021;99:319–320. (https://doi
.org/10.2471/BLT.20.267724, accessed 1 Feb 2023) [PMC free article: PMC8085627] [PubMed: 33953450] - Austria, Belgium, Finland, France, Hungary, Ireland, Latvia, Lithuania, Luxembourg, Poland, Portugal, Slovakia, & Slovenia. Non-paper – Novel stimuli for the development and keeping on the market of antimicrobials. Based on an initiative from the Kingdom of the Netherlands, and is supported by Austria, Belgium, Finland, France, Hungary, Ireland, Latvia, Lithuania, Luxembourg, Poland, Portugal, Slovakia, and Slovenia. Kingdom of the Netherlands. 2022. (https://www
.permanentrepresentations .nl/documents /publications /2022/12/01/novel-stimuli-for-the-development-and-keeping-on-the-market-of-antimicrobials, accessed 1 Feb 2023) - Baraldi E, et al. Antibiotic pipeline coordinators. Journal of Law, Medicine & Ethics . 2018;46 S1:25–31. (https://doi
.org/10.1177/1073110518782912, accessed 1 Feb 2023) [PubMed: 30146958] - Baraldi E, et al. Economic incentives for the development of new antibiotics: Report commissioned by the Public Health Agency of Sweden . Uppsala University; 2019. (https://www
.diva-portal .org/smash/get/diva2:1283298 /FULLTEXT01.pdf, accessed 1 Feb 2023) - BCG & Wellcome Trust. Understanding the antibiotic manufacturing ecosystem: A view of global supply chains, pressure points, and implications for antimicrobial resistance response . Boston Consulting Group and Wellcome Trust; 2021. (https://www
.amr-insights .eu/wp-content/uploads /2022/04/Publicatie-Understanding-the-antibiotic-manufacturing-ecosystem-2022_BCG.pdf, accessed 1 Feb 2023) - Berdud M, et al. Study of the potential use of an EU Transferable Exclusivity Extension (TEE) to incentivize antibiotic R&D . London: OHE; 2019. (https://efpia
.eu/media /637070/ohe-study-of-the-potential-use-of-an-eu-transferable-exclusivity-extension-tee-to-incentivize-antibiotic-rd .pdf, accessed 1 Feb 2023) - Boluarte T, Schulze U. The case for a subscription model to tackle antimicrobial resistance . BCG Global; 2022. (https://www
.bcg.com/publications /2022/model-for-tackling-antimicrobial-resistance, accessed 7 Nov 2022) - Booton RD, et al. One Health drivers of antibacterial resistance: quantifying the relative impacts of human, animal and environmental use and transmission. One Health . 2021;12:100220. (https://doi
.org/10.1016/j .onehlt.2021.100220, accessed 1 Feb 2023) [PMC free article: PMC7892992] [PubMed: 33644290] - Boulet P, et al. Advanced purchase agreements for COVID-19 vaccines: analysis and comments . Brussels: Study for The Left in the European Parliament; 2021. (https://left
.eu/content /uploads/2021/07/Advanced-purchase-agreements-1.pdf, accessed 1 Feb 2023) - Boyer B, Kroetsch A, Ridley D. Design of a transferable exclusivity voucher program: Incentives for drug and vaccine development for neglected diseases . Duke: Margolis Center for Health Policy; 2022. (https:
//healthpolicy .duke.edu/sites/default /files/2022-01/Transferable %20Exclusivity %20Voucher%20Program.pdf, accessed 1 Feb 2023) - Brogan DM, Mossialos E. Applying the concepts of financial options to stimulate vaccine development. Nat Rev Drug Discov. . 2006;5(8):641–7. (https://doi
.org/10.1038/nrd2035, accessed 1 Feb 2023) [PubMed: 16883302] - Brogan DM, Mossialos E. Incentives for new antibiotics: The Options Market for Antibiotics (OMA) model. Global Health . 2013;9:58. (https://doi
.org/10.1186/1744-8603-9-58, accessed 1 Feb 2023) [PMC free article: PMC4226193] [PubMed: 24199835] - Brogan DM, Mossialos E. Systems, not pills: The options market for antibiotics seeks to rejuvenate the antibiotic pipeline. Soc Sci Med. . 2016;151:167–72. (https://doi
.org/10.1016/j .socscimed.2016.01.005, accessed 1 Feb 2023) [PubMed: 26808335] - Bundeministerium der Justiz. Verordnung über die Nutzenbewertung von Arzneimitteln nach § 35a Absatz 1 SGB V für Erstattungsvereinbarungen nach § 130b SGB V (Arzneimittel-Nutzenbewertungsverordnung – AM-NutzenV) § 5 Zusatznutzen . undated. (https://www
.gesetze-im-internet .de/am-nutzenv/__5.html, accessed 7 Nov 2022) - CARB-X. Stewardship & Access Plan (SAP) Development Guide . Combating Antibiotic Resistant Bacteria, led by Boston University; 2021. (https://carb-x
.org/wp-content /uploads/2021 /03/Stewardship__Access_DevGuide_2021 .pdf, accessed 1 Feb 2023) - Cassini A, et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. The Lancet Infectious Diseases . 2018;19(1):56–66. (https://doi
.org/10.1016 /S1473-3099(18)30605-4, accessed 1 Feb 2023) [PMC free article: PMC6300481] [PubMed: 30409683] - Cecchini M, Lee S. Low-value health care with high stakes: Promoting the rational use of antimicrobials. In: Couffinhal A, editor. Tackling wasteful spending on health . Paris: OECD Publications; 2017. (https://doi
.org/10.1787 /9789264266414-6-en, accessed 1 Feb 2023) - CEPS. Accord cadre du 31/12/2015 entre le Comité économique des produits de santé et les entreprises du médicament (Leem) . Paris: Comité économique des produits de santé (CEPS); 2015. (https://sante
.gouv.fr /IMG/pdf/accord_cadre _version_definitive_20151231-2.pdf, accessed 1 Feb 2023) - Clack L, et al. Implementing infection prevention practices across European hospitals: an in-depth qualitative assessment. BMJ Quality & Safety . 2018;27(10):771–780. (https://doi
.org/10.1136 /bmjqs-2017-007675, accessed 1 Feb 2023) [PMC free article: PMC6166596] [PubMed: 29950324] - Cohen B, et al. Factors associated with variation in estimates of the cost of resistant infections. Medical Care . 2010;48(9):767–775. (https://doi
.org/10.1097/MLR .0b013e3181e358b9, accessed 1 Feb 2023) [PMC free article: PMC2924922] [PubMed: 20706168] - Colson AR, et al. Antimicrobial resistance: is health technology assessment part of the solution or part of the problem? Value in Health . 2021;24(12):1828–1834. (https://doi
.org/10.1016/j .jval.2021.06.002, accessed 1 Feb 2023) [PubMed: 34838281] - Copenhagen Economics. Study on the economic impact of supplementary protection certificates, pharmaceutical incentives and rewards in Europe . Brussels: European Commission; 2018. (https:
//copenhageneconomics .com/wp-content /uploads/2021/12/copenhagen-economics-2018-study-on-the-economic-impact-of-spcs-pharmaceutical-incentives-and-rewards-in-europe.pdf, accessed 1 Feb 2023) - Council of the European Union. Council Recommendation of 7 December 2018 on strengthened cooperation against vaccine-preventable diseases . Brussels: Official Journal of the European Union: C466/1; 2018. (https://eur-lex
.europa .eu/legal-content/EN /TXT/PDF/?uri=CELEX:32018H1228(01), accessed 1 Feb 2023) - Danish Medicines Agency. Guideline on the “sunset clause” – notification about initiation or cessation of marketing of medicinal products . Copenhagen: Danish Medicines Agency; 2022. (https:
//laegemiddelstyrelsen .dk/en/licensing /licensing-of-medicines /marketing-authorisation /sunset-clause, accessed 15 Jan 2023) - Darrow JJ, Kesselheim AS. Incentivizing antibiotic development: Why isn’t the Generating Antibiotic Incentives Now (GAIN) Act working? Open Forum Infectious Diseases . 2020;7(1):ofaa001. (https://doi
.org/10.1093/ofid/ofaa001, accessed 1 Feb 2023) [PMC free article: PMC6986775] [PubMed: 32016125] - Dental and Pharmaceutical Benefits Agency. et al. Mission to strengthen access to older antibiotics – mapping and proposals for measures [Uppdrag att stärka tillgången till äldre antibiotika – kartläggning och förslag till åtgärder] . Tandvårds- och Läkemedelsförmånsverket (TLV); 2022. (https://www
.tlv.se/download/18 .5e8c1abc18461f354fbec5b /1672233413137 /uppdrag_att _starka_tillgangen_till _aldre_antibiotika_slutrapport.pdf, accessed 1 Feb 2023) - ECDC. Assessing the health burden of infections with antibiotic-resistant bacteria in the EU/EEA, 2016–2020 . European Centre for Disease Prevention and Control; 2022a. (https://www
.ecdc.europa .eu/en/publications-data /health-burden-infections-antibiotic-resistant-bacteria-2016-2020, accessed 1 Feb 2023) - ECDC. Infographic: Total antibiotic consumption in humans . European Centre for Disease Prevention and Control; 2022b. (https://www
.ecdc.europa .eu/en/publications-data /infographic-total-antibiotic-consumption-humans, accessed 3 Dec 2022) - ECRAID. Reducing the impact of infectious diseases . European Clinical Research Alliance for Infectious Diseases; undated. About us (https://www
.ecraid.eu/about-us, accessed 19 Nov 2022) - EDCTP. Funding clinical research for medical tools to detect, treat and prevent poverty-related infectious diseases in sub-Saharan Africa . The Hague: European and Developing Countries Clinical Trials Partnership; undated. (https://www
.edctp.org, accessed 2 Dec 2022) - EFPIA. A new EU pull incentive to address antimicrobial resistance (AMR): Recommendations from EFPIA . EFPIA & Charles River Associates; 2022. (https://www
.efpia.eu /media/636464/a-new-eu-pull-incentive-to-address-anti-microbial-resistance-amr .pdf, accessed 1 Feb 2023) - EMA. Addendum to the guideline on the evaluation of medicinal products indicated for treatment of bacterial infections . Amsterdam: European Medicines Agency; 2014. (https://www
.ema.europa .eu/en/documents/scientific-guideline /addendum-guideline-evaluation-medicinal-products-indicated-treatment-bacterial-infections_en.pdf, accessed 1 Feb 2023) - EMA. Fees payable to the European Medicines Agency . Amsterdam: European Medicines Agency; 2022a. (https://www
.ema.europa .eu/en/human-regulatory /overview/fees-payable-european-medicines-agency, accessed 5 Dec 2022) - EMA. Notifying a change of marketing status . Amsterdam: European Medicines Agency; 2022b. (https://www
.ema.europa .eu/en/human-regulatory /post-authorisation /notifying-change-marketing-status, accessed 1 Feb 2023) - EPHA, ReAct. Antibiotic incentives in the revision of EU pharmaceutical legislation: Joint Position Paper . European Public Health Alliance & ReAct; 2022. (https://epha
.org/wp-content /uploads/2022 /07/antibiotic-incentives-pharma-legislation-joint-paper-2022.pdf, accessed 1 Feb 2023) - Espín J, et al. How can voluntary cross-border collaboration in public procurement improve access to health technologies in Europe? Policy Brief 21. Copenhagen: European Observatory on Health Systems and Policies; 2016. (https://apps
.who.int /iris/handle/10665/331985, accessed 1 Feb 2023) [PubMed: 29144633] - EU-JAMRAI. Incentivising antibiotic access and innovation . EU Joint Action on Antimicrobial Resistance and Healthcare-Associated Infections; 2021. (https://epha
.org/wp-content /uploads/2021 /01/eu-jamrai-hub-incentives-policy-brief-incentivizing-antibiotic-access-and-innovation.pdf, accessed 1 Feb 2023) - European Commission. Pharmaceutical Strategy for Europe . Brussels: European Commission; 2020. COM(2020) 761 final (https://eur-lex
.europa .eu/legal-content/EN /TXT/?uri=CELEX:52020DC0761, accessed 1 Feb 2023) - European Commission. Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use . Brussels: European Commission; 2001. (https://www
.ema.europa .eu/en/documents/regulatory-procedural-guideline /directive-2001 /83/ec-european-parliament-council-6-november-2001-community-code-relating-medicinal-products-human-use_en.pdf, accessed 1 Feb 2023) - European Commission, et al. Future-proofing pharmaceutical legislation: Study on medicine shortages – Final report (revised) . Luxembourg: Publications Office of the European Union; 2021. (https://doi
.org/10.2875/211485, accessed 1 Feb 2023) - European Commission. EU Global Health Strategy: Better health for all in a changing world . Luxembourg: Publications Office of the European Union; 2022a. (https://health
.ec.europa .eu/system/files /2022-12/international _ghs-report-2022_en.pdf, accessed 1 Feb 2023) - European Commission. HERA AMR feasibility study on stockpiling – D6/D7 Final report . Luxembourg: Publications Office of the European Union; 2022b. (https://op
.europa.eu /en/publication-detail /-/publication/c68221dd-80e0-11ed-9887-01aa75ed71a1, accessed 1 Feb 2023) - European Commission. Regulation (EU) 2022/123 of the European Parliament and of the Council of 25 January 2022 on a reinforced role for the European Medicines Agency in crisis preparedness and management for medicinal products and medical devices (Text with EEA relevance) . Brussels: Official Journal of the European Union; 2022c. (https://eur-lex
.europa .eu/legal-content/EN /TXT/PDF/?uri=CELEX:32022R0123, accessed 1 Feb 2023) - European Commission. Vulnerabilities of the global supply chains of medicines: Structured dialogue on the security of medicines supply (working document). European Commission: Public Health; 2022d. (https://health
.ec.europa .eu/latest-updates /staff-working-document-vulnerabilities-global-supply-chains-medicines-structured-dialogue-security-2022-10-17_en, accessed 1 Feb 2023) - European Commission. Global Europe: Neighbourhood, Development and International Cooperation Instrument . Brussels: European Commission: International Partnerships; 2023a. (https:
//international-partnerships .ec.europa .eu/funding/funding-instruments /global-europe-neighbourhood-development-and-international-cooperation-instrument_en, accessed 15 Jan 2023) - European Commission. Team Europe Initiatives . Brussels: European Commission: International Partnerships; 2023b. (https:
//international-partnerships .ec.europa .eu/policies/team-europe-initiatives_en, accessed 15 Jan 2023) - European Commission. et al. Study on best practices in the public procurement of medicines: Final report . Luxembourg: Publications Office of the European Union; 2022. (https://op
.europa.eu /en/publication-detail /-/publication/ca856a7f-7c37-11ed-9887-01aa75ed71a1 /language-en /format-PDF/source-278040684, accessed 1 Feb 2023) - FAO. AMR Multi-Stakeholder Partnership Platform . Rome: Food and Agriculture Organization of the UN; 2023. (https://www
.fao.org/antimicrobial-resistance /quadripartite/the-platform/en, accessed 1 Feb 2023) - Federal Institute for Drugs and Medical Devices. FAQ ‘Sunset clause’ . 2022. (https://www
.bfarm.de /EN/Medicinal-products /_FAQ/Licensing/Variations /Sunset-clause-notification-procedure/_node.html, accessed 15 Jan 2023) - Forman R, Anderson M, Jit M, Mossialos E. Ensuring access and affordability through COVID-19 vaccine research and development investments: A proposal for the options market for vaccines. Vaccine, 3. 2020;38(39):6075–6077. (https://doi
.org/10.1016/j .vaccine.2020.07.068, accessed 1 Feb 2023) [PMC free article: PMC7834564] [PubMed: 32773244] - Forman R, Mossialos E. The EU Response to COVID-19: From Reactive Policies to Strategic Decision-Making. J Common Mark Stud . 2021 Nov 10;59 Suppl 1:56–68. (https://doi
.org/10.1111/jcms.13259, accessed 1 Feb 2023) [PMC free article: PMC8657336] [PubMed: 34903899] - Forman R, et al. Drawing light from the pandemic: Rethinking strategies for health policy and beyond. Health Policy . 2022;126(1):1–6. (https://doi
.org/10.1016/j .healthpol.2021.12.001, accessed 1 Feb 2023) [PMC free article: PMC8645287] [PubMed: 34961678] - G20 Research Group. Chair’s Summary: Health Ministers’ of the G20 Meeting, Bali . G20 Research Group; Bali: 2022. 28 Oct 2022 (http://www
.g20.utoronto .ca/2022/221028-health.html, accessed 15 Jan 2023) - Glover RE, Knight GM, Chandler CIR. Antimicrobial resistance at the G7. BMJ . 2021;373:n1417. (https://doi
.org/10.1136/bmj.n1417, accessed 1 Feb 2023) [PubMed: 34083377] - Gotham D, et al. Reimbursement models to tackle market failures for antimicrobials: Approaches taken in France, Germany, Sweden, the United Kingdom, and the United States. Health Policy . 2021;125(3):296–306. (https://doi
.org/10.1016/j .healthpol.2020.11.015, accessed 1 Feb 2023) [PubMed: 33402265] - Gross AE. The effect of a piperacillin/tazobactam shortage on antimicrobial prescribing and Clostridium difficile risk in 88 US medical centers. Clinical Infectious Diseases . 2017;65(4):613–618. (https://doi
.org/10.1093/cid/cix379, accessed 1 Feb 2023) [PubMed: 28444166] - Hansen S, et al. Organization of infection control in European hospitals. Journal of Hospital Infection . 2015;91(4):338–345. (https://doi
.org/10.1016/j .jhin.2015.07.011, accessed 1 Feb 2023) [PubMed: 26542950] - HM Government. Development of new antibiotics encouraged with new pharmaceutical payment system . London: GOV.UK; 2019. (https://www
.gov.uk/government /news/development-of-new-antibiotics-encouraged-with-new-pharmaceutical-payment-system, accessed 9 Sep 2019) - Hwang TJ, et al. Impact of the priority review voucher program on drug development for rare pediatric diseases. Health Affairs . 2019;38(2):313–319. (https://doi
.org/10.1377/hlthaff .2018.05330, accessed 1 Feb 2023) [PubMed: 30715972] - IMI. Innovative Health Initiative . Innovative Medicines Initiative; 2021. (http://www
.imi.europa .eu/about-imi/innovative-health-initiative, accessed 25 Nov 2022) - IMI AMR Accelerator. The AMR Accelerator . Innovative Medicines Initiative AMR Accelerator; undated. About us (https:
//amr-accelerator.eu/about-us/, accessed 31 Dec 2022) - IQVIA. The global use of medicines 2022: Outlook to 2026 . Durham, US: IQVIA; 2022. (https://www
.iqvia.com /insights/the-iqvia-institute /reports/the-global-use-of-medicines-2022, accessed 1 Feb 2023) - Klein EY, et al. Assessment of WHO antibiotic consumption and access targets in 76 countries, 2000–15: an analysis of pharmaceutical sales data. The Lancet Infectious Diseases . 2021;21(1):107–11. (https://doi
.org/10.1016 /S1473-3099(20)30332-7, accessed 1 Feb 2023) [PubMed: 32717205] - Kostyanev T. The Innovative Medicines Initiative’s New Drugs for Bad Bugs programme: European public–private partnerships for the development of new strategies to tackle antibiotic resistance. Journal of Antimicrobial Chemotherapy . 2016;71(2):290–295. (https://doi
.org/10.1093/jac/dkv339, accessed 1 Feb 2023) [PubMed: 26568581] - Lacotte Y, et al. on behalf of the European Union Joint Action on Antimicrobial Resistance and Healthcare-Associated Infections (EU-JAMRAI). Infection prevention and control research priorities: what do we need to combat healthcare-associated infections and antimicrobial resistance? Results of a narrative literature review and survey analysis. Antimicrobial Resistance & Infection Control . 2020;9:142. (https://doi
.org/10.1186 /s13756-020-00801-x, accessed 1 Feb 2023) - McEvoy E, Ferri D. The role of the joint procurement agreement during the COVID-19 pandemic: Assessing its usefulness and discussing its potential to support a European Health Union. European Journal of Risk Regulation . 2020;11 S4:851–863. (accessed 1 Feb 2023)
- Medicines for Europe. Note on transferable vouchers . Brussels: Medicines for Europe; 2022. (https://www
.medicinesforeurope .com/wp-content /uploads/2022/03 /Medicines-for-Europe-Note-on-Transferable-Vouchers-March-2022.pdf, accessed 1 Feb 2023) - MedSafe. Licensed medicine manufacturing sites . New Zealand Medicines and Medical Devices Safety Authority; 2022. (https://www
.medsafe.govt .nz/regulatory/licensed.asp, accessed 3 Nov 2022) - Mestrovic T, et al. The burden of bacterial antimicrobial resistance in the WHO European region in 2019: a cross-country systematic analysis. The Lancet Public Health . 2022;7(11):E897–E913. (https://doi
.org/10.1016 /S2468-2667(22)00225-0, accessed 1 Feb 2023) [PMC free article: PMC9630253] [PubMed: 36244350] - Meyer RJ. Priority review vouchers: GAO report provides scant evidence of success. Clinical and Translational Science . 2021;14(1):8–10. (https://doi
.org/10.1111/cts.12878, accessed 1 Feb 2023) [PMC free article: PMC7877854] [PubMed: 32949480] - Miljković N, Polidori P, Kohl S. Managing antibiotic shortages: lessons from EAHP and ECDC surveys. European Journal of Hospital Pharmacy . 2022;29(2):90–94. (https://doi
.org/10.1136 /ejhpharm-2021-003110, accessed 1 Feb 2023) [PMC free article: PMC8899686] [PubMed: 35190453] - Miller SI. Antibiotic resistance and regulation of the Gram-negative bacterial outer membrane barrier by host innate immune molecules. mBio . 2016;7(5):e01541–16. (https://doi
.org/10.1128/mBio.01541-16, accessed 1 Feb 2023) [PMC free article: PMC5040116] [PubMed: 27677793] - Morel CM, Mossialos E. Stoking the antibiotic pipeline. BMJ . 2010;340:c2115. (https://doi
.org/10.1136/bmj.c2115, accessed 1 Feb 2023) [PubMed: 20483950] - Mossialos E, et al., editors. Health systems governance in Europe: The role of European Union law and policy . 1st edn. New York: Cambridge University Press; 2010a. (https://www
.euro.who .int/__data/assets/pdf_file /0006/138147/E94886_prelims.pdf, accessed 1 Feb 2023) - Mossialos, et al. Policies and incentives for promoting innovation in antibiotic research . Copenhagen: European Observatory on Health Systems and Policies; 2010b. (https://www
.euro.who .int/__data/assets/pdf_file /0011/120143/E94241.pdf, accessed 1 Feb 2023) - Mrazek MF, Mossialos E. Stimulating pharmaceutical research and development for neglected diseases. Health Policy . 2003;64(1):75–88. (https://doi
.org/10.1016 /s0168-8510(02)00138-0, accessed 1 Feb 2023) [PubMed: 12644330] - Murray CJ, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet . 2022;399(10325):629–655. (https://doi
.org/10.1016 /S0140-6736(21)02724-0, accessed 1 Feb 2023) [PMC free article: PMC8841637] [PubMed: 35065702] - NICE. Models for the evaluation and purchase of antimicrobials . London: National Institute for Health and Care Excellence; undated. (https://www
.nice.org .uk/about/what-we-do /life-sciences/scientific-advice /models-for-the-evaluation-and-purchase-of-antimicrobials, accessed 25 Nov 2022) - OECD. Stemming the superbug tide: Just a few dollars more . Paris: OECD Publishing; 2018. (https://www
.oecd.org /health/stemming-the-superbug-tide-9789264307599-en.htm, accessed 1 Feb 2023) - OECD. Antimicrobial resistance: Tackling the burden in the European Union . European Centre for Disease Prevention and Control; 2019. (https://www
.oecd.org /health/health-systems /AMR-Tackling-the-Burden-in-the-EU-OECD-ECDC-Briefing-Note-2019.pdf, accessed 1 Feb 2023) - Outterson K, Samora JB, Keller-Cuda K. Will longer antimicrobial patents improve global public health? Lancet Infect Dis. . 2007;7(8):559–66. (https://doi
.org/10.1016 /S1473-3099(07)70188-3, accessed 1 Feb 2023) [PubMed: 17646029] - Outterson K, McDonnell A. Funding Antibiotic Innovation With Vouchers: Recommendations On How To Strengthen A Flawed Incentive Policy. Health Aff (Millwood), 1. 2016;35(5):784–90. (https://doi
.org/10.1377/hlthaff .2015.1139, accessed 1 Feb 2023) [PubMed: 27140983] - Outterson K. Estimating the appropriate size of global pull incentives for antibacterial medicines. Health Affairs . 2021;40(11):1758–1765. (https://doi
.org/10.1377/hlthaff .2021.00688, accessed 1 Feb 2023) [PubMed: 34724432] - Outterson K, Rex JH. Evaluating for-profit public benefit corporations as an additional structure for antibiotic development and commercialization. Translational Research . 2020;220:182–190. (https://doi
.org/10.1016/j .trsl.2020.02.006, accessed 1 Feb 2023) [PubMed: 32165059] - Outterson K, et al. Antimicrobial resistance: What’s at stake and what are we doing about it? Washington: Health Affairs Forefront; 2022a. (https://doi
.org/10.1377/forefront .20220302.628551, accessed 1 Feb 2023) - Outterson K, et al. Patient access in 14 high-income countries to new antibacterials approved by the US Food and Drug Administration, European Medicines Agency, Japanese Pharmaceuticals and Medical Devices Agency, or Health Canada, 2010–2020. Clinical Infectious Diseases . 2022b;74(7):1183–1190. (https://doi
.org/10.1093/cid/ciab612, accessed 1 Feb 2023) [PMC free article: PMC8994582] [PubMed: 34251436] - Payne DJ, et al. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nature Reviews Drug Discovery . 2007;6:29–40. (https://doi
.org/10.1038/nrd2201, accessed 1 Feb 2023) [PubMed: 17159923] - PLATINEA. Background . Uppsala University: PLATINEA; 2023. (https://www
.platinea .se/about-platinea/background, accessed 15 Jan 2023) - Pownell A. G-BA defines 4 strict requirements on cefiderocol use to protect its “reserve antibiotics” status . German Market Access Simplified; 2022. (https:
//germanmarketaccesssimplified .com /reserve-antibiotics-g-ba, accessed 7 Nov 2022) - Public Health Agency of Sweden. Questions and answers – Agreements signed for a pilot study of a new reimbursement model . Solna: Public Health Agency of Sweden; 2019. (https://www
.folkhalsomyndigheten .se/contentassets /c09fd6d5d42243e097be216767686c08 /questions_answers _agreements_signed_pilot _study_new_reimbursement_model.pdf, accessed 1 Feb 2023) - Public Health Agency of Sweden. Availability of antibiotics . Solna: Public Health Agency of Sweden; 2020. (https://www
.folkhalsomyndigheten .se/the-public-health-agency-of-sweden /communicable-disease-control /antibiotics-and-antimicrobial-resistance /availability-of-antibiotics, accessed 2 Nov 2022) - Public Health Agency of Sweden. Availability of certain antibiotics – A pilot study of an alternative reimbursement model. [Tillgänglighet till vissa antibiotika – En pilotstudie av en alternativ ersättningsmodell] . Solna: Public Health Agency of Sweden; 2023. (https://www
.folkhalsomyndigheten .se/publikationer-och-material /publikationsarkiv /t/tillganglighet-till-vissa-antibiotika-en-pilotstudie-av-en-alternativ-ersattningsmodell/, accessed 1 Feb 2023) - Pulcini C, et al. Forgotten antibiotics: An inventory in Europe, the United States, Canada, and Australia. Clinical Infectious Diseases . 2012;54(2):268–274. (https://doi
.org/10.1093/cid/cir838, accessed 1 Feb 2023) [PubMed: 22198992] - Pulcini C. Forgotten antibiotics: A follow-up inventory study in Europe, the USA, Canada and Australia. International Journal of Antimicrobial Agents . 2017;49(1):98–101. (https://doi
.org/10.1016/j .ijantimicag.2016.09.029, accessed 1 Feb 2023) [PubMed: 27887966] - ReAct. Antibiotic pollution: India scores a global first with effluent limits . ReAct: News and Opinions; 2020a. (https://www
.reactgroup .org/news-and-views /news-and-opinions/year-2020 /antibiotic-pollution-india-scores-a-global-first-with-effluent-limits, accessed 27 Nov 2022) - ReAct. Shortages and AMR – why should we care? 4 consequences of antibiotic shortages . ReAct: News and Opinions; 2020b. (https://www
.reactgroup .org/news-and-views /news-and-opinions/year-2020 /shortages-and-amr-why-should-we-care-4-consequences-of-antibiotic-shortages, accessed 3 Nov 2022) - ReAct. Ensuring sustainable access to effective antibiotics for everyone – everywhere . 2021. (https://www
.reactgroup .org/wp-content/uploads /2021/09/ReAct-Report-Ensuring-sustainable-access-to-effective-antibiotics-for-everyone-everywhere-How-to-address-the-global-crisis-in-antibiotic-Research-and-Development-March-2021.pdf, accessed 1 Feb 2023) - Renwick M, Mossialos E. What are the economic barriers of antibiotic R&D and how can we overcome them? Expert Opinion on Drug Discovery . 2018;13(10):889–892. (https://doi
.org/10.1080/17460441 .2018.1515908, accessed 1 Feb 2023) [PubMed: 30175625] - Renwick MJ, Brogan DM, Mossialos E. A systematic review and critical assessment of incentive strategies for discovery and development of novel antibiotics. Journal of Antibiotics . 2016;69:73–88. (https://doi
.org/10.1038/ja.2015.98, accessed 1 Feb 2023) [PMC free article: PMC4775540] [PubMed: 26464014] - Renwick MJ, Simpkin V, Mossialos E. Targeting innovation in antibiotic drug discovery and development: the need for a One Health – One Europe – One World Framework . Copenhagen: European Observatory on Health Systems and Policies; 2016. (https://pubmed
.ncbi.nlm.nih.gov/28806044, accessed 1 Feb 2023) [PubMed: 28806044] - REPAIR Impact Fund. REPAIR Impact Fund . REPAIR Impact Fund; undated. About (https://www
.repair-impact-fund.com/about, accessed 2 Dec 2022) - Review on Antimicrobial Resistance. Tackling drug-resistant infections globally: Final report and recommendations . The Review on Antimicrobial Resistance; 2016. chaired by Jim O’Neill (https://amr-review
.org /sites/default/files /160518_Final%20paper_with%20cover.pdf, accessed 1 Feb 2023) - Rex JH, Outterson K. Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approach. The Lancet Infectious Diseases . 2016;16(4):500–505. (https://doi
.org/10.1016 /S1473-3099(15)00500-9, accessed 1 Feb 2023) [PubMed: 27036356] - Ridley DB. Priorities for the priority review voucher. American Journal of Tropical Medicine and Hygiene . 2017;96(1):14–15. (https://doi
.org/10.4269/ajtmh.16-0600, accessed 1 Feb 2023) [PMC free article: PMC5239680] [PubMed: 27573624] - Rothery C, et al. Framework for value assessment of new antimicrobials: implications of alternative funding arrangements for NICE Appraisal . Policy Research Unit in Economic Evaluation of Health and Care Interventions (EEPRU); 2018. (https://pure
.york.ac .uk/portal/en/publications /framework-for-value-assessment-of-new-antimicrobials-implications, accessed 1 Feb 2023) - Schaffer SK, et al. Assessing the value of new antibiotics: Additional elements of value for health technology assessment decisions . London: Office of Health Economics Research; 2017. (https:
//ohemasterclassseries .com/wp-content /uploads/2021/03/OHE-AIM-Assessing-The-Value-of-New-Antibiotics-May-2017.pdf, accessed 1 Feb 2023) - Shafiq N, et al. Shortage of essential antimicrobials: A major challenge to global health security. BMJ Global Health . 2021;6(11):e006961. (https://doi
.org/10.1136 /bmjgh-2021-006961, accessed 1 Feb 2023) [PMC free article: PMC8565534] [PubMed: 34728479] - Sharma P, Towse A. New drugs to tackle antimicrobial resistance: Analysis of EU policy options . London: Office of Health Economics; 2011. (https://www
.ohe.org/publications /new-drugs-tackle-antimicrobial-resistance-analysis-eu-policy-options, accessed 1 Feb 2023) - Silver LL. Challenges of antibacterial discovery. Clinical Microbiology Reviews . 2011;24(1):71–109. (https://doi
.org/10.1128/CMR.00030-10, accessed 1 Feb 2023) [PMC free article: PMC3021209] [PubMed: 21233508] - Simpkin VL, et al. Incentivising innovation in antibiotic drug discovery and development: progress, challenges and next steps. Journal of Antibiotics . 2017;70:1087–1096. (https://doi
.org/10.1038/ja.2017.124, accessed 1 Feb 2023) [PMC free article: PMC5746591] [PubMed: 29089600] - Smith R, Coast J. The true cost of antimicrobial resistance. BMJ . 2013;346:f1493. (https://doi
.org/10.1136/bmj.f1493, accessed 1 Feb 2023) [PubMed: 23479660] - So AD, et al. Towards new business models for R&D for novel antibiotics. Drug Resist Updat . 2011;14(2):88–94. (https://doi
.org/10.1016/j .drup.2011.01.006, accessed 1 Feb 2023) [PubMed: 21439891] - Ståhlgren G, Grape M, Edlund C. The Swedish model for prioritising research on the use of antibiotics: Aligning public funding with research gaps. Health Policy . 2022;126(8):725–730. (https://doi
.org/10.1016/j .healthpol.2022.05.012, accessed 1 Feb 2023) [PubMed: 35637052] - Stern S, et al. Breaking through the wall: A call for concerted action on antibiotics research . Bundesministerium für Gesundheit; 2017. (https://www
.bundesgesundheitsministerium .de/service/publikationen /details/breaking-through-the-wall-a-call-for-concerted-action-on-antibiotics-research-and-development.html, accessed 1 Feb 2023) - Sulis G, et al. Exposure to World Health Organization’s AWaRe antibiotics and isolation of multidrug resistant bacteria: A systematic review and meta-analysis. Clinical Microbiology and Infection . 2022;28(9):1193–1202. (https://doi
.org/10.1016/j .cmi.2022.03.014, accessed 1 Feb 2023) [PubMed: 35339675] - Tansarli GS, et al. Impact of antimicrobial multidrug resistance on inpatient care cost: an evaluation of the evidence. Expert Review of Anti-infect Therapy . 2013;11(3):321–331. (https://doi
.org/10.1586/eri.13.4, accessed 1 Feb 2023) [PubMed: 23458771] - Tebano G, et al. Essential and forgotten antibiotics: An inventory in low- and middle-income countries. International Journal of Antimicrobial Agents . 2019;54(3):273–282. (https://doi
.org/10.1016/j .ijantimicag.2019.06.017, accessed 1 Feb 2023) [PubMed: 31260741] - Theuretzbacher U, et al. Challenges and shortcomings of antibacterial discovery projects. Clinical Microbiology and Infection . 2022. S1198-743X(22)00600-0 (https://doi
.org/10.1016/j .cmi.2022.11.027, accessed 1 Feb 2023) [PMC free article: PMC10160915] [PubMed: 36503116] - Thomas D, Wessel C. The state of innovation in actibacterial therapeutics . Biotechnology Innovation Organization: BIO Industry Analysis; 2022. (https://www
.bio.org/sites /default/files/2022-02 /The-State-of-Innovation-in-Antibacterial-Therapeutics.pdf, accessed 1 Feb 2023) - TIFAC. Active pharmaceutical ingredients: Status, issues, technology readiness, and challenges . Technology Information Forecasting and Assessment Council; 2020. (https://www
.tifac.org .in/images/pdf/2020papers /API_Report_-Released _on_July_10_2020.pdf, accessed 1 Feb 2023) - UK Government. Sunset clause: Request for public health exemption . London: GOV.UK; 2022. (https://www
.gov.uk/government /publications /sunset-clause-request-for-public-health-exemption, accessed 15 Jan 2023) - UN General Assembly. High-level plenary meeting on antimicrobial resistance . United Nations Digital Library; 2016. 71st sess.: 2016–2017. (https:
//digitallibrary .un.org/record/842813?ln=en, accessed 1 Feb 2023) - Uppsala University. What ENABLE-2 can do for you . Uppsala University: Department of Medicinal Chemistry; undated. (https://www
.ilk.uu.se/enable2/for-you, accessed 19 Nov 2022) - US Congress. H.R.2182 – 112th Congress (2011-2012): Generating Antibiotic Incentives Now Act of 2011 . Congress.gov; 2011. (https://www
.congress .gov/bill/112th-congress/house-bill/2182, accessed 7 Nov 2022) - US Congress. To establish a program to develop antimicrobial innovations targeting the most challenging pathogens and most threatening infections . 2020. (https://www
.congress .gov/bill/117th-congress /house-bill/3932/text, accessed 1 Feb 2023) - Wallace D. Sandoz strikes €150m deal on antibiotics in Austria. Generics Bulletin . 2020 (https://generics
.pharmaintelligence .informa .com/GB150110/Sandoz-Strikes-150m-Deal-On-Antibiotics-In-Austria, accessed 5 Dec 2022) - Wellcome Trust. Clinical trial networks for antibiotic development: Why they’re important and how they should be developed . London: Wellcome Trust; 2016. (https://wellcome
.org /sites/default/files /clinical-trial-networks-for-antibiotic-development-wellcome-oct16.pdf, accessed 1 Feb 2023) - Wellcome Trust. Drug-resistant infections: the science is on track, but the economics need fixing . London: Wellcome Trust; 2020. News (https://wellcome
.org /news/drug-resistant-infections-science-economics, accessed 11 Feb 2022) - WHO. The WHO Global Surveillance and Monitoring System for Substandard and Falsified Medical Products . World Health Organization; 2017a. (https://apps
.who.int /iris/bitstream/handle /10665/326708/9789241513425-eng .pdf?sequence =1&isAllowed=y, accessed 1 Feb 2023) - WHO. WHO publishes list of bacteria for which new antibiotics are urgently needed . World Health Organization,; 2017b. News (https://www
.who.int/news /item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed, accessed 25 Nov 2022) - WHO. Thirteenth General Programme of Work 2019−2023 . World Health Organization; 2019. What we do (https://www
.who.int/about /what-we-do/thirteenth-general-programme-of-work-2019---2023, accessed 1 Dec 2022) - WHO. 2021 AWaRe classification . World Health Organization: Publications overview; 2021a. (https://www
.who.int/publications-detail-redirect /2021-aware-classification, accessed 26 Nov 2022) - WHO. Ensuring the availability of off-patent antibiotics . World Health Organization; 2021b. (https://cdn
.who.int/media /docs/default-source /2021-dha-docs/who_pars_flyer_en .pdf?sfvrsn=fd628f76_8, accessed 1 Feb 2023) - WHO. 2021 Antibacterial agents in clinical and preclinical development: an overview and analysis. World Health Organization; 2022a. (https://www
.who.int/publications /i/item/9789240047655, accessed 1 Feb 2023) - WHO. Quadripartite welcomes new political commitments in fight against antimicrobial resistance . World Health Organization; 2022b. News (https://www
.who.int/news /item/25-11-2022-quadripartite-welcomes-new-political-commitments-in-fight-against-antimicrobial-resistance, accessed 15 Jan 2023) - Wilsdon T, Robson A, Lu L. A framework for assessing the potential net benefits realised through Transferable Exclusivity Extension (TEE) as an incentive for development of novel antimicrobials: Final Report . London: Charles River Associates; 2022. (https://www
.efpia.eu /media/676634/cra-efpia-a-framework-for-assessing-the-costs-and-benefits-of-tee-final-report.pdf, accessed 1 Feb 2023) - World Bank. Drug-resistant infections: A threat to our economic future . World Bank; 2017. Health (https://www
.worldbank .org/en/topic/health /publication/drug-resistant-infections-a-threat-to-our-economic-future, accessed 1 Feb 2023) - World Economics. G20: Economics . London: World Economics; 2022. (https://www
.worldeconomics .com/Regions/G20/default.aspx, accessed 31 Dec 2022) - Wouters OJ, McKee M, Luyten J. Estimated research and development investment needed to bring a new medicine to market, 2009–2018. JAMA . 2020;323(9):844–853. (https://doi
.org/10.1001/jama.2020.1166, accessed 1 Feb 2023) [PMC free article: PMC7054832] [PubMed: 32125404] - Zingg W, et al. Hospital organisation, management, and structure for prevention of health-care-associated infection: a systematic review and expert consensus. The Lancet Infectious Diseases . 2015;15(2):212–224. (https://doi
.org/10.1016 /S1473-3099(14)70854-0, accessed 1 Feb 2023) [PubMed: 25467650]
- References - How can the EU support sustainable innovation and access to effecti...References - How can the EU support sustainable innovation and access to effective antibiotics?
Your browsing activity is empty.
Activity recording is turned off.
See more...